SALL4 and hepatocellular carcinoma: Interestingly, recent studies showed that SALL4 is a neosubstrate of the molecular glue thalidomide and its derivatives that degrade its target proteins via the E3 ligase complex system [49,50], suggesting that thalidomide and its derivatives could be used for treatment of high metabolic HCC tumors in the future.